What is the best adjunct medication to add to citalopram 20 mg for depression?

Best Adjunct Medication for Depression on Citalopram 20 mg

Based on the highest quality evidence, augmentation with bupropion SR is the recommended first-line adjunct to citalopram 20 mg for treatment-resistant depression, as it demonstrated similar efficacy to other augmentation strategies but with significantly fewer discontinuations due to adverse events compared to buspirone (12.5% vs. 20.6%, p<0.001). 1

Evidence-Based Augmentation Strategy

First-Line Augmentation Options

The 2023 American College of Physicians guideline, analyzing the landmark STAR*D trial, found that augmentation strategies with bupropion SR, buspirone, or cognitive therapy showed similar efficacy when added to citalopram 1. However, the critical distinction lies in tolerability:

• Bupropion SR: 12.5% discontinuation rate due to adverse events
• Buspirone: 20.6% discontinuation rate due to adverse events (significantly higher, p<0.001)
• Cognitive therapy: 9.2% discontinuation rate

While cognitive therapy had the lowest discontinuation rate, bupropion SR offers the practical advantage of being a medication option with good tolerability and proven efficacy 1.

Alternative Augmentation Considerations

Aripiprazole showed higher remission rates (55.4% vs. 34.0%, p=0.031) compared to bupropion in one trial, though this study had high risk of bias 1. Given the FDA warnings about QTc prolongation with citalopram 2, adding an antipsychotic that can also prolong QTc requires careful cardiac monitoring.

Critical Safety Considerations with Citalopram

Before adding any augmentation agent, you must address these FDA-mandated concerns 2:

Maximum dose restrictions apply:

• Citalopram should NOT exceed 20 mg/day (your patient's current dose) if they are:
  • Over 60 years old
  • CYP2C19 poor metabolizers
  • Taking CYP2C19 inhibitors (omeprazole, cimetidine)
  • Have hepatic impairment

Cardiac monitoring requirements:

• Baseline and periodic ECG monitoring if patient has cardiac risk factors
• Check electrolytes (potassium, magnesium) before initiating augmentation
• Discontinue if QTc >500 ms
• Avoid combining with other QTc-prolonging medications 2

Switch vs. Augmentation Decision

The guideline evidence shows no significant difference between switching antidepressants versus augmenting 1. Two trials with 1,231 participants found equivalent efficacy and safety whether switching from an SSRI to mirtazapine or augmenting with mirtazapine 1.

Choose augmentation (adding bupropion SR) when:

• Patient has had partial response to citalopram
• Patient tolerates citalopram well
• No cardiac contraindications exist

Choose switching when:

• Patient has had no response to adequate citalopram trial
• Significant side effects from citalopram
• QTc prolongation concerns (citalopram causes dose-dependent QTc prolongation) 2

Emerging Options for Treatment-Resistant Cases

If multiple adequate trials fail, the 2022 VA/DoD guideline now suggests ketamine infusion or intranasal esketamine for patients who haven't responded to several pharmacologic trials 3. These show significant improvement in depressive symptoms within 24 hours, with effects persisting up to 7 days when added to ongoing antidepressant treatment 3.

Common Pitfalls to Avoid

1. Do not exceed citalopram 40 mg/day under any circumstances due to QTc prolongation risk 2
2. Screen for bipolar disorder before augmenting—antidepressant monotherapy or augmentation may precipitate manic episodes 2
3. Monitor for serotonin syndrome when combining medications, especially with bupropion which has some serotonergic activity 2
4. Check drug interactions: Citalopram is metabolized by CYP3A4 and CYP2C19; inhibitors of these enzymes increase citalopram levels and QTc risk 2

Practical Implementation

Bupropion SR augmentation protocol:

• Start bupropion SR 150 mg once daily for 3-4 days
• Increase to 150 mg twice daily (target dose)
• Maximum 400 mg/day if needed
• Reassess response at 4-6 weeks
• Monitor blood pressure (bupropion can increase BP)

If bupropion fails or is contraindicated (seizure history, eating disorders), consider switching to a different antidepressant class (venlafaxine XR, duloxetine, or mirtazapine) rather than further augmentation strategies, as the evidence shows equivalent outcomes 1.